AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Roxadustat (evrenzo) — Worldwide product sales by Year
Roxadustat (evrenzo) — Worldwide product sales ($M) ($M)
AstraZeneca Roxadustat (evrenzo) — Worldwide product sales: $274M in FY2025, down 17.2% from a year earlier.
Where the FY2025 figure comes from
“|| roxadustat | 274 | (17) | (17) | - | - | 274 | (17) | (17) | - | - | - | - | - | -”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Roxadustat (evrenzo) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 274 | -17.2% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 331 | +22.1% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 271 | +37.6% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 197 | +13.2% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 174 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up roxadustat (evrenzo) — Worldwide product sales
- Roxadustat (evrenzo) — Worldwide YoY actual (%)-17.0% · FY2025
- Roxadustat (evrenzo) — Worldwide YoY CER (%)-17.0% · FY2025
- Roxadustat (evrenzo) — US product sales ($M)0 · FY2025
- Roxadustat (evrenzo) — Emerging Markets product sales ($M)274 · FY2025
- Roxadustat (evrenzo) — Europe product sales ($M)0 · FY2025
- Roxadustat (evrenzo) — Established RoW product sales ($M)0 · FY2025
Cite this data
StockData. (2026). AstraZeneca Roxadustat (evrenzo) — Worldwide product sales ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-roxadustat-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.